These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 36073639)

  • 21. The number of stents was an independent risk of stent restenosis in patients undergoing percutaneous coronary intervention.
    Tang L; Cui QW; Liu DP; Fu YY
    Medicine (Baltimore); 2019 Dec; 98(50):e18312. PubMed ID: 31852115
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term clinical and angiographic outcomes of percutanenous coronary intervention with everolimus-eluting stents for the treatment of cardiac allograft vasculopathy.
    Cheng R; Vanichsarn C; Patel JK; Currier J; Chang DH; Kittleson MM; Makkar R; Kobashigawa JA; Azarbal B
    Catheter Cardiovasc Interv; 2017 Jul; 90(1):48-55. PubMed ID: 27862865
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SWEDEHEART-1-year data show no benefit of newer generation drug-eluting stents over bare-metal stents in patients with severe kidney dysfunction following percutaneous coronary intervention.
    Edfors R; James S; Szummer K; Evans M; Carrero JJ; Faxén J; Persson J; Spaak J; Varenhorst C; Jernberg T; Lagerqvist B
    Coron Artery Dis; 2020 Jan; 31(1):49-58. PubMed ID: 31658144
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relationship between left coronary artery bifurcation angle and restenosis after stenting of the proximal left anterior descending artery.
    Konishi T; Yamamoto T; Funayama N; Nishihara H; Hotta D
    Coron Artery Dis; 2016 Sep; 27(6):449-59. PubMed ID: 27214275
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Single-stent crossover technique from distal unprotected left main coronary artery to the left circumflex artery.
    Naganuma T; Chieffo A; Basavarajaiah S; Takagi K; Costopoulos C; Latib A; Carlino M; Montorfano M; Bernelli C; Nakamura S; Colombo A
    Catheter Cardiovasc Interv; 2013 Nov; 82(5):757-64. PubMed ID: 23674385
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel predictor of restenosis and adverse cardiac events: asymmetric dimethylarginine.
    Ari H; Ari S; Erdoğan E; Tiryakioğlu O; Ustündağ Y; Huysal K; Koca V; Bozat T
    Heart Vessels; 2010 Jan; 25(1):19-26. PubMed ID: 20091394
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of chronic kidney disease on a re-percutaneous coronary intervention for sirolimus-eluting stent restenosis.
    Aoyama Y; Hirayama H; Ishii H; Kobayashi K; Ishikawa K; Takigawa M; Nanasato M; Yoshida Y; Aoyama T; Yoshikawa D; Matsubara T; Murohara T
    Coron Artery Dis; 2012 Dec; 23(8):528-32. PubMed ID: 22975841
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison between catheter-based delivery of paclitaxel after bare-metal stenting and drug-eluting stents in coronary artery disease patients at high risk for in-stent restenosis.
    El-Mokadem M; El-Ramly M; Hassan A; Boshra H; AbdelWahab A
    Cardiovasc Revasc Med; 2017 Dec; 18(8):596-600. PubMed ID: 28625402
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of clinical outcomes using stents versus no stents after percutaneous coronary intervention for proximal left anterior descending versus proximal right and left circumflex coronary arteries.
    Ashby DT; Dangas G; Mehran R; Lansky AJ; Narasimaiah R; Iakovou I; Polena S; Satler LF; Pichard AD; Kent KM; Stone GW; Leon MB
    Am J Cardiol; 2002 May; 89(10):1162-6. PubMed ID: 12008168
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incidence of Restenosis Following Rapamycin or Paclitaxeleluting Stent in Coronary Stent Implantation.
    Shakarami A
    Cardiovasc Hematol Disord Drug Targets; 2021; 21(3):196-201. PubMed ID: 34886782
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Contributors to newly developed coronary artery disease in patients with a previous history of percutaneous coronary intervention beyond the early phase of restenosis.
    Endo A; Yoshida Y; Kageshima K; Sato H; Suga T; Nasu H; Takahashi N; Tanabe K
    Intern Med; 2014; 53(8):819-28. PubMed ID: 24739601
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sustained risk of stent thrombosis and restenosis in first generation drug-eluting Stents after One Decade of Follow-up: A Report from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR).
    Völz S; Angerås O; Odenstedt J; Ioanes D; Haraldsson I; Dworeck C; Redfors B; Råmunddal T; Albertsson P; Petursson P; Omerovic E
    Catheter Cardiovasc Interv; 2018 Nov; 92(6):E403-E409. PubMed ID: 29745465
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Initial and late efficacy of everolimus-eluting stents for small and non-small coronary lesions from evaluating delayed late loss study.
    Tama N; Uzui H; Horita Y; Namura M; Tada H
    Heart Vessels; 2017 Dec; 32(12):1415-1423. PubMed ID: 28687988
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incidence and predictors of restenosis after coronary stenting in 10 004 patients with surveillance angiography.
    Cassese S; Byrne RA; Tada T; Pinieck S; Joner M; Ibrahim T; King LA; Fusaro M; Laugwitz KL; Kastrati A
    Heart; 2014 Jan; 100(2):153-9. PubMed ID: 24270744
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Three-years outcomes of diabetic patients treated with coronary bioresorbable scaffolds.
    Anadol R; Schnitzler K; Lorenz L; Weissner M; Ullrich H; Polimeni A; Münzel T; Gori T
    BMC Cardiovasc Disord; 2018 May; 18(1):92. PubMed ID: 29743023
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outcomes of small coronary artery stenting with bare-metal stents versus drug-eluting stents: results from the NHLBI Dynamic Registry.
    Parikh SV; Luna M; Selzer F; Marroquin OC; Mulukutla SR; Abbott JD; Holper EM
    Catheter Cardiovasc Interv; 2014 Feb; 83(2):192-200. PubMed ID: 21735515
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 3-Year Clinical Follow-Up of the RIBS IV Clinical Trial: A Prospective Randomized Study of Drug-Eluting Balloons Versus Everolimus-Eluting Stents in Patients With In-Stent Restenosis in Coronary Arteries Previously Treated With Drug-Eluting Stents.
    Alfonso F; Pérez-Vizcayno MJ; Cuesta J; García Del Blanco B; García-Touchard A; López-Mínguez JR; Masotti M; Zueco J; Cequier A; Velázquez M; Moreno R; Mainar V; Domínguez A; Moris C; Molina E; Rivero F; Jiménez-Quevedo P; Gonzalo N; Fernández-Pérez C;
    JACC Cardiovasc Interv; 2018 May; 11(10):981-991. PubMed ID: 29798776
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcomes after percutaneous coronary intervention with stents in patients treated with thoracic external beam radiation for cancer.
    Liang JJ; Sio TT; Slusser JP; Lennon RJ; Miller RC; Sandhu G; Prasad A
    JACC Cardiovasc Interv; 2014 Dec; 7(12):1412-20. PubMed ID: 25459527
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Angiography and Optical Coherence Tomography Assessment of the Drug-Coated Balloon ESSENTIAL for the Treatment of In-Stent Restenosis.
    de la Torre Hernández JM; Garcia Camarero T; Lozano Ruiz-Poveda F; Urbano-Carrillo CA; Sánchez Pérez I; Cano-García M; Saez R; Andrés Morist A; Molina E; Pinar E; Torres A; Lezcano EJ; Gutierrez H; Arnold RJ; Zueco J
    Cardiovasc Revasc Med; 2020 Apr; 21(4):508-513. PubMed ID: 31401071
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intravascular Brachytherapy for the Management of Repeated Multimetal-Layered Drug-Eluting Coronary Stent Restenosis.
    Varghese MJ; Bhatheja S; Baber U; Kezbor S; Chincholi A; Chamaria S; Buckstein M; Bakst R; Kini A; Sharma S
    Circ Cardiovasc Interv; 2018 Oct; 11(10):e006832. PubMed ID: 30354630
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.